Clinical Trial Detail

NCT ID NCT03374488
Title Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Incyte Corporation
Indications

urethra transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

Therapies

Epacadostat + Pembrolizumab

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.